10-Q: Shineco Inc. Reports Mixed Results in Q3 2024, Revenue Growth Offset by Increased Losses

Sentiment:

Quarterly Report 15 May 2024 5:06 PM

Shineco Inc. experienced significant revenue growth in the third quarter of 2024, primarily driven by recent acquisitions, but also saw a substantial increase in net losses due to higher operating expenses.

Capital raiseThe company entered into a securities purchase agreement on March 27, 2024, to sell up to 285,714 shares of common stock for gross proceeds of up to $285,714.The company has received gross proceeds in full from the investors as of March 31, 2024, and no share has been issued as of the date of this report.

Worse than expectedThe company's net loss from continuing operations increased significantly, indicating a worsening financial performance despite revenue growth.The company's working capital turned negative, suggesting a deterioration in its short-term financial health.The company's cash and cash equivalents decreased substantially, raising concerns about its liquidity.

Summary

Shineco Inc. reported a net loss of $4.08 million for the nine months ended March 31, 2024, compared to a net loss of $7.82 million for the same period in 2023.
The company's revenue increased significantly to $5.30 million for the nine months ended March 31, 2024, up from $0.23 million in the same period of 2023.
This revenue growth was primarily driven by the acquisitions of Biowin and Wintus, which contributed to the rapid diagnostic and other products and other agricultural products segments, respectively.
Operating expenses also increased substantially to $12.45 million for the nine months ended March 31, 2024, compared to $6.12 million in the same period of 2023.
The company's net loss from continuing operations was $12.94 million for the nine months ended March 31, 2024, compared to a net loss of $6.89 million for the same period in 2023.
Shineco reported a net income from discontinued operations of $8.86 million for the nine months ended March 31, 2024, compared to a net loss of $0.94 million for the same period in 2023, due to the disposal of the Tenet-Jove business.
The company's working capital was negative $20.9 million as of March 31, 2024, compared to a positive working capital of $17.6 million as of June 30, 2023.
The company's cash and cash equivalents decreased to $0.57 million as of March 31, 2024, from $15.4 million as of March 31, 2023.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with strong revenue growth offset by significant losses and liquidity concerns. The company's future is uncertain, and the risks are substantial, leading to a negative sentiment.

Positives

The company experienced a substantial increase in revenue, primarily due to recent acquisitions.
The company reported a net income from discontinued operations of $8.86 million for the nine months ended March 31, 2024, due to the disposal of the Tenet-Jove business.
The company has taken steps to address material weaknesses in internal controls.

Negatives

The company's net loss from continuing operations increased significantly.
Operating expenses increased substantially, offsetting the revenue gains.
The company's working capital is negative, indicating potential liquidity issues.
The company's cash and cash equivalents decreased significantly.

Risks

The company has a history of recurring net losses and negative cash flow from operations, raising substantial doubt about its ability to continue as a going concern.
The company's operations are primarily located in the PRC, exposing it to political, economic, and legal risks.
The company relies on related party transactions and loans, which may pose risks.
The company's financial results are subject to fluctuations in foreign currency exchange rates.
The company's ability to maintain compliance with Nasdaq listing requirements is uncertain.

Future Outlook

Management believes that the measures taken to enhance liquidity will provide sufficient resources for the company to meet its future liquidity needs for the next 12 months. The company plans to develop new products, expand its distribution network, and grow through mergers and acquisitions.

Management Comments

Management believes that the measures taken to enhance liquidity will provide sufficient resources for the company to meet its future liquidity needs for the next 12 months.
Management expects that the Company will be able to renew its existing bank loans upon their maturity based on past experience and its good credit history.

Industry Context

The company's expansion into rapid diagnostic products, agricultural products, and healthy meals reflects a broader trend of diversification and growth in the health and wellness sector. The company's focus on the Chinese market aligns with the increasing demand for health-related products and services in the region.

Comparison to Industry Standards

Shineco's revenue growth is significant compared to previous periods, but the increase in net losses is concerning.
The company's negative working capital is a red flag, indicating potential liquidity issues that are not typical for established companies in the health and wellness sector.
The company's reliance on related party transactions and loans is a risk factor that is not common among larger, more established companies.
The company's financial performance is not directly comparable to larger, more established companies in the health and wellness sector due to its unique business model and recent acquisitions.
The company's performance is not directly comparable to companies that have not recently undergone a reverse stock split or a major restructuring of their business segments.

Legal Proceedings

The company settled a lawsuit with Ms. Guiqin Li in January 2023, paying approximately $0.7 million.
The company settled a lawsuit with Lei Zhang and Yan Li in December 2023, waiving a subscription receivable of $3,024,000.

Related Party Transactions

The company has made temporary advances to certain stockholders and senior management of the Company and to other entities that are either owned by family members of those stockholders or to other entities that the Company has investments in.
The company had related party payables of $2,276,248 as of March 31, 2024.
The company made sales of $797,506 to its related party, Chongqing Fuling District Renyi Zhilu Silk Industry Co., Ltd, for the nine months ended March 31, 2024.
The company pledged real estate property with a net book value of $1,045,883 as collateral to guarantee a personal loan of Mr. Yuying Zhang, the former chairman of the Board and legal representative of Tenet-Jove.

Stakeholder Impact

Shareholders face significant risks due to the company's negative working capital, increased losses, and potential delisting from Nasdaq.
Employees may be affected by the company's financial instability and potential restructuring.
Customers may experience disruptions in service or product availability due to the company's financial challenges.
Suppliers may face increased credit risk due to the company's financial instability.
Creditors face increased risk of non-payment due to the company's negative working capital and increased losses.

Next Steps

The company plans to develop new products and expand its distribution network.
The company intends to grow its business through possible mergers and acquisitions of similar or synergetic businesses.
The company expects to renew its existing bank loans upon their maturity.

Key Dates

Date	Description
2003-12-15	Tenet-Jove was incorporated.
2006-07-14	Tenet-Jove was granted the status of a wholly foreign-owned entity.
2016-12-10	Tenet-Jove entered into a purchase agreement with Tianjin Tajite.
2017-09-30	Tenet-Jove established Xinjiang Shineco Taihe Agriculture Technology Ltd. and Xinjiang Tianyi Runze Bioengineering Co., Ltd.
2019-03-13	Tenet-Jove established Beijing Tenjove Newhemp Biotechnology Co., Ltd.
2019-05-05	Two minority shareholders of Tianjin Tajite transferred their 26.4% of the equity interest to the Company.
2020-07-23	Shanghai Jiaying International Trade Co., Ltd. was established.
2021-01-07	Inner Mongolia Shineco Zhonghemp Biotechnology Co., Ltd. was established.
2021-06-08	Tenet-Jove entered into a Restructuring Agreement.
2021-06-16	The Company entered into a Securities Purchase Agreement and issued an unsecured convertible promissory note.
2021-07-16	The Company entered into a Securities Purchase Agreement and issued two unsecured convertible promissory notes.
2021-08-19	The Company entered into a Securities Purchase Agreement and issued an unsecured convertible promissory note.
2021-12-07	The Company established Shineco Life Science Research Co., Ltd.
2022-04-13	The Company established Shineco Life Science Group Hong Kong Co., Limited.
2022-04-24	The Company entered into a Share Transfer Agreement with Life Science HK.
2022-06-13	The Company entered into a stock purchase agreement with certain non-U.S. investors.
2022-07-20	The Companys shareholders approved the offer and sale of the Shares at a meeting of the shareholders of the Company.
2022-07-26	The closing for the offer and sale of the Shares occurred.
2022-08-10	The Company entered into a securities purchase agreement with certain non-US investors.
2022-10-21	The Company, through its wholly-owned subsidiary, Life Science, entered into a stock purchase agreement with the Seller and Biowin.
2022-12-29	Life Science closed the acquisition of 51% of the issued equity interests of Changzhou Biowin Pharmaceutical Co., Ltd.
2023-01-12	The Board of the Company approved the sales of 72,222 shares of the Companys common stock to the Companys employees.
2023-05-16	Fuzhou Meida Health Management Co., Ltd and Shinkang Technology (Jiangsu) Co., Ltd were established.
2023-05-23	Life Science established Beijing Shineco Chongshi Information Consulting Co., Ltd.
2023-05-29	Life Science HK entered into a stock purchase agreement with Dream Partner Limited, Chongqing Wintus Group, and certain shareholders of Dream Partner.
2023-06-15	The Company signed a second extension amendment with the Investor to extend the maturity date of the convertible note.
2023-06-18	The Company entered into a certain securities purchase agreement with a non-U.S. investor.
2023-06-20	The Company entered into a certain stock purchase agreement with certain non-U.S. investors.
2023-08-29	The Board of Directors of the Company approved the issuance of shares of common stock pursuant to the Companys 2022 Plan.
2023-09-18	The Company closed the Acquisition of Wintus.
2023-09-27	The Company entered into a loan agreement with a third party.
2023-12-22	The Company entered into a securities purchase agreement with certain non-US investors.
2024-02-02	The Companys stockholders approved a 1-for-10 reverse stock split.
2024-02-16	The 1-for-10 reverse stock split became effective.
2024-03-27	The Company entered into a securities purchase agreement with certain non-US investors.
2024-05-15	As of this date, there were 6,445,963 shares of common stock outstanding.

Keywords

Shineco, financial results, revenue, net loss, acquisitions, Biowin, Wintus, operating expenses, discontinued operations, reverse stock split, working capital, liquidity, China, rapid diagnostic products, agricultural products, healthy meals

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.